Complement
description
Transcript of Complement
Complement: History
Discovered in 1894 by Bordet
It was used to refer to a heat-labile serum component
Its lytic activity destroyed when heated at 56°C for 30 min
However it is now known that complement contributes to many other functions
Complement Functions
• Host benefit:– opsonization to enhance phagocytosis– phagocytes attraction and activation– lysis of bacteria and infected cells– regulation of antibody responses– clearance of immune complexes– clearance of apoptotic cells
• Host detriment:– Inflammation, anaphylaxis
Proteins of the complementsystem
Complement comprises over 20 different serum proteins
These proteins are produced by a variety of cells:
Hepatocytes, macrophages, gut epithelial cells
Some components can bind to Immunoglobulins
While others are proenzymes that when activated can cleave and activate other components
Proteins of the complementsystem (nomenclature)
5
C1(q r s), C2, C3, C4, C5, C6, C7, C8, C9
factors B, D, H and I, properdin (P)
mannose binding lectin (MBL), MBL associated serine proteases (MASP-1 MASP-2)
C1 inhibitor (C1-INH, serpin), C4-binding protein (C4-BP), decay accelerating factor (DAF), Complement receptor 1 (CR1), protein-S (vitronectin)
• C-activation: alteration of C proteins such that they interact with the next component
• C-fixation: utilization of C by Ag-Ab complexes
• Hemolytic units (CH50): dilution of serum which lyses 50% of a standardized suspension of Ab-coated R.B.Cs
• C-inactivation: denaturation (usually by heat) of an early C-component resulting in loss of hemolytic activity
• Convertase/esterase: altered C-protein which acts as a proteolytic enzyme for another C-component
Definitions
Activation product of complement proteins (nomenclature)
When enzymatically cleaved, the larger moiety, binds to the activation complex or membrane and the smaller peptide is released into the microenvironment
Letter “b” is usually added to the larger, membrane-binding, peptide and “a” to the smaller peptide (e.g., C3b/C3a, C4b/C4a, C5b/C5a)
EXCEPTION: C2 (the larger, membrane-binding moiety is C2a; the smaller one is C2b)
Activated component are usually over-lined: e.g. C1qrs
Pathways of complement activation
CLASSICALPATHWAY
ALTERNATIVEPATHWAY
activationof C5
LYTIC ATTACKPATHWAY
antibodydependent
LECTINPATHWAY
antibodyindependent
Activation of C3 andgeneration of C5 convertase
Components of the Classical Pathway
C4C2 C3
C1 complex
Ca++
C1r C1s
C1q
Ca++
C1r C1s
C1q
C4
C4a
b
Classical Pathway Generation of C3-convertase
Classical Pathway Generation of C3-convertase
C4b
Mg++
C4a
Ca++
C1r C1s
C1q
C2
C2ba
C2a
_____
C4b2a is C3 convertase
Classical Pathway Generation of C5-convertase
C4b
Mg++
C4a
Ca++
C1r C1s
C1q
C2b
C2a
C3
C3a
b
________
C4b2a3b is C5 convertase; it leads into the Membrane
Attack Pathway
13
Biological Activities of Classical Pathway Components
Component Biological Activity
C2b Prokinin; cleaved by plasmin to yield kinin, which results in edema
C3a Anaphylotoxin; can activate basophils and mast cells to degranulate resulting in increased vascular permeability and contraction of smooth muscle cells, which may lead to anaphylaxis
C3b Opsonin
Activation of phagocytic cells
C4a Anaphylaotoxin
C4b Opsonin
14
Control of Classical Pathway Components
Component Regulation
All C1-inhibitor (C1-INH); dissociates C1r and C1s from C1q
C3a C3a-inactivator (C3a-INA; Carboxypeptidase B)
C3b Factors H and I; Factor H facilitates the degradation of C3b by Factor I
C4a C3a-INH
C4b C4 binding protein (C4-BP) and Factor I; C4-BP facilitates degradation of C4b by Factor I; C4-BP also prevents the association of C2a with C4b thus blocking formation of C3 convertase
Components of mannose-binding (lectin) pathway
15
Mannose Binding Lectin (MBL),
which binds to bacterial surface with mannose-containing polysaccharides
MBL associated serine proteases (MASP-1 MASP-2)
Components of mannose-binding lectin pathway
C4
MBL C2 MASP1
MASP2
Mannose-binding lectin pathway
C4
MBL
C4b
C4a
C4b
C2
C2b
C2a
C2a
_____
C4b2a is C3 convertase; it will lead to the generation of
C5 convertaseMASP1
MASP2
Components of thealternative pathway
18
C3
factors B & D
properdin (P)
Control and regulation of the alternative pathway
Factor I & H DAF Complement receptor 1
19
The alternative pathway can be activated by:
Many gram-negative bacteria:
Neisseria meningitidis and N. gonorrhoea
Some gram-positive bacteriaCertain viruses and parasitesAggregated immunoglobulina(particularly IgA)
20
the result is lysis of these
organisms
Activation of the alternative pathway
Spontaneous hydrolysis of C3 to produce C3i C3i cleaves Factor B into Bb The C3iBb complex acts as C3 convertase(has
very short half life) Once C3b is formed Factor B binds to it and
becomes susceptible to cleavage by Factor D C3bBb is a more stable C3 convertase which
continues to generate more C3b(amplfication loop)
21
Components of thealternative pathway
C3 B
D
P
Degradation of spontaneously produced C3b
C3b
C3b
iC3biC3b
II
C3dgC3dg
C3c C3c
C3b stabilization andC5 activation
When C3b finds the appropriate surface it binds to factor B, which is cleaved by Factor D to produce C3 convertase(C3bBb) (which is more stable)
C3 convertase(C3bBb) is further stabilized by Poperdin
24
C3b stabilization andC5 activation
C3b
C3b finds an activator (protector) membrane
C3
C3a
bB
D
b
PThis is stable C5 convertase
of the alternative pathway
C3b regulation on self and activator surfaces
C3b
C5-convertase of the two pathways
C3b Bb C3b
C5-convertase of the Alternative Pathway
C4b C2a C3b
C5-convertase of the Classical and lectin
Pathways
Generation of C5 convertase leads to the activation of the
Lytic pathway
Lytic pathway
Components of the lytic pathway
C6
C9
C8
C7C5
Lytic pathway
C5-convertase (of the Classical and lectin
Pathways or the Alternative Pathway) cleaves C5 into C5a & C5b
C5b associates with C6 &C7 and insrets into the cell membrane
Then C8 binds, followed by several molecules of C9
C9 molecules form a pore in the membrane C5bC6C7C8C9 is MAC
30
Biological effects of C5a
Product Biological Effects Regulation
Biological properties of C-activation products
C2b (prokinin) edema C1-INH
C3a (anaphylatoxin)
mast cell degranulation; enhanced vascular permeability; anaphylaxis
carboxy-peptidase- B (C3-INA)
Product Biological Effects Regulation
Biological properties of C-activation products
as C3, but less potent
(C3-INA)C4a (anaphylatoxin)
opsonization; phagocytosis
C4b (opsonin)
C4-BP, factor I
C3b (opsonin)
opsonization; phagocyte activation
factors H & I
Product Biological Effects Regulation
Biological properties of C-activation products
anaphylactic as C3, but much more potent;attracts & activates PMN causes neutrophil aggregation, stimulation of oxidative metabolism and leukotriene release
C5a (chemotactic factor)
carboxy-peptidase-B (C3-INA)
C5b67 protein-Schemotaxis, attaches to other membranes
35
Complement Deficiencies and DiseaseClassical Pathway
Pathway Component Disease Mechanism
C1INH HereditaryAngioedema
Overproduction of C2b (prokinin)
C1, C2, C4 Predisposition to SLE
Opsonization of immunecomplexes help keepthem soluble, deficiencyresults in increasedprecipitation in tissuesand inflammation
36
Complement Deficiencies and DiseaseLectin Pathway
Pathway Component Disease Mechanism
MBL Susceptibility to bacterial infections in infants orimmunosuppressed
Inability to initiate lectin pathway
37
Complement Deficiencies and DiseaseAlternative Pathway
Pathway/Component Disease Mechanism
Factors B or D Susceptibility to pyogenic (pus-forming) bacterial infections
Lack of sufficient opsonization of bacteria
C3 Susceptibility to bacterial infections
Lack of opsonization and inability to utilize the membrane attack pathway
C5, C6, C7 C8, or C9
Susceptibility to Gram-negative infections
Inability to attack the outer membrane of Gram-negative bacteria
38
Complement Deficiencies and DiseaseAlternative Pathway cont.
Pathway Component Disease Mechanism
Properdin (X-linked) Susceptibility meningococcal meningitis
Lack of opsonization of bacteria
Factors H or I C3 deficiency and susceptibility to bacterial infections
Uncontrolled activation of C3 via alternative pathway resulting in depletion of C3